Following an invitation from Greek authorities, a team of experts from the ECDC Programme for HIV/AIDS, Sexually Transmitted and Blood-borne infections, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the WHO Regional Office for Europe will visit Greece on 28 and 29 May 2012. The European Union Agency for Fundamental Rights (FRA) will join the mission as observers.
In an expert meeting in Stockholm, identified synergies and gaps in the availability of sexual health data, programmes, initiatives and policies across Europe and possibilities for future work will be discussed.
WHO “SAVE LIVES: Clean Your Hands” is an annual campaign that makes part of major global effort to support healthcare workers to improve hand hygiene practices in healthcare settings, and thus support the prevention of often life-threatening healthcare-associated infections.
This study found a marked reduction in vaccine serotype carriage after PCV7 implementation. The overall pneumococcal, H. influenzae and S. aureus carriage decreased slightly, but not significantly.
This workshop enabled all to agree on the relevance of EPIS VPD to be used as a platform for the reporting and monitoring of measles outbreak in the EU, agree on the type of information to be reported, the nature of outbreaks to be notified and the further usage by ECDC (e.g. European Monthly Measles Monitoring1) and other Member States of data that will be shared through EPIS VPD by countries.
A meeting and a workshop on the ECDC point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use in acute care hospitals took take place in London on 5-6 March 2012.
This workshop brought together experts on HIV monitoring and reporting from EU Member States, ECDC, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the European Commission, UNAIDS, the World Health Organization and the Civil Society Forum.
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine.